As of Thursday close, Navidea Biopharmaceuticals Inc.’s (AMEX:NAVB) stock was down -$0.01, moving down -9.38 percent to $0.09. The average number of shares traded per day over the past five days has been 6,024,600 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0071 gain in that time frame. In the last twenty days, the average volume was 3,850,355, while in the previous 50 days, it was 7,930,054.
Since last month, NAVB stock retreated -26.27%. Shares of the company fell to $0.0626 on 08/07/23, the lowest level in the past month. A 52-week high of $0.53 was reached on 02/08/23 after having rallying from a 52-week low of $0.06. Since the beginning of this year, NAVB’s stock price has dropped by -58.57% or -$0.1230, and marked a new high 4 times. However, the stock has declined by -83.66% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
In the three months ended September 29, Navidea Biopharmaceuticals Inc.’s quick ratio stood at 0.10, while its current ratio was 0.10, showing that the company is not able to pay off its debt. Based on annual data, NAVB earned -$0.12 million in gross profit and brought in $66000.0 in revenue.
While analysts expected Navidea Biopharmaceuticals Inc. to report -$0.11 quarterly earnings, the actual figure was -$0.08 per share, beating the consensus estimate by 27.30%. During the quarter, the company generated -$2.29 million in EBITDA. The liabilities of Navidea Biopharmaceuticals Inc. were 9.01 million at the end of its most recent quarter ended September 29, and its total debt was $1.34 million. The value of shareholders’ equity is $99.83 million.
Technical Picture
This quick technical analysis looks at Navidea Biopharmaceuticals Inc.’s (NAVB) price momentum. With a historical volatility rate of 192.33%, the RSI 9-day stood at 53.93% on 17 August.
With respect to its five-day moving average, the current Navidea Biopharmaceuticals Inc. price is up by +8.89% percent or $0.0071. At present, NAVB shares trade -20.91% below its 20-day simple moving average and -70.00% percent below its 100-day simple moving average. However, the stock is currently trading approximately +2.35% above its SMA50 and -62.60% below its SMA200.
Stochastic coefficient K was 49.95% and Stochastic coefficient D was 37.89%, while ATR was 0.0128. Given the Stochastic reading of 52.81% for the 14-day period, the RSI (14) reading has been calculated as 50.16%.
Analyst Ratings
Aegis Capital reiterated its a Hold rating on Navidea Biopharmaceuticals Inc. (AMEX: NAVB) in a note to investors. The analysts firm has however raised their price target to $2, representing a possible 97.0% increase in the stock price. Navidea Biopharmaceuticals Inc. (NAVB) has been rated Buy by analysts. According to 0 brokerage firms, NAVB is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Navidea Biopharmaceuticals Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $8.00, the current consensus forecast for the stock is $8.00 – $8.00. Based on these forecasts, analysts predict Navidea Biopharmaceuticals Inc. (NAVB) will achieve an average price target of $8.00.
